Perbak Capital Partners LLP Purchases Shares of 2,799 Thermo Fisher Scientific Inc. (NYSE:TMO)

Perbak Capital Partners LLP purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,799 shares of the medical research company’s stock, valued at approximately $1,456,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AdvisorShares Investments LLC grew its position in Thermo Fisher Scientific by 20.8% during the 4th quarter. AdvisorShares Investments LLC now owns 13,451 shares of the medical research company’s stock worth $6,998,000 after acquiring an additional 2,316 shares during the last quarter. Northern Trust Corp boosted its position in shares of Thermo Fisher Scientific by 13.2% in the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company’s stock worth $2,034,107,000 after purchasing an additional 455,004 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Thermo Fisher Scientific by 18.1% during the 4th quarter. The Manufacturers Life Insurance Company now owns 1,676,267 shares of the medical research company’s stock worth $872,044,000 after buying an additional 256,682 shares during the period. Optiver Holding B.V. raised its stake in Thermo Fisher Scientific by 55.1% during the 4th quarter. Optiver Holding B.V. now owns 591 shares of the medical research company’s stock worth $307,000 after buying an additional 210 shares during the period. Finally, Quarry LP bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $531,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on TMO shares. Raymond James reaffirmed an “outperform” rating and set a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. StockNews.com lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Friday. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Finally, Citigroup reduced their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $616.95.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $421.55 on Tuesday. The company has a 50 day simple moving average of $485.08 and a two-hundred day simple moving average of $525.48. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12 month low of $409.85 and a 12 month high of $627.88. The stock has a market cap of $159.13 billion, a price-to-earnings ratio of 25.50, a PEG ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter last year, the firm earned $5.11 EPS. The business’s revenue was up .2% compared to the same quarter last year. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.41%. Thermo Fisher Scientific’s payout ratio is currently 10.09%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares of the company’s stock, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock valued at $13,106,062 over the last three months. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.